Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Sebaceous Hyperplasia

  • Author: Daniel J Hogan, MD; Chief Editor: William D James, MD  more...
 
Updated: Jun 18, 2015
 

Background

Sebaceous hyperplasia is a common, benign condition of sebaceous glands in adults of middle age or older. Lesions can be single or multiple and manifest as yellowish, soft, small papules on the face (particularly nose, cheeks, and forehead). Sebaceous hyperplasia occasionally also occurs on the chest,[1] areola,[2] mouth,[3] scrotum,[4] foreskin,[5] shaft of penis,[6] and vulva.[7, 8, 9] Rarely reported variants have included a giant form,[10] a linear or zosteriform arrangement, a diffuse form, and a familial form. Juxtaclavicular beaded lines are an additional variant characterized by closely placed papules arranged in parallel rows.[11] Lesions of sebaceous hyperplasia are benign, with no known potential for malignant transformation, but may be associated with nonmelanoma skin cancer in transplantation patients.[12, 13, 14]

Some authorities consider rhinophyma to represent a special form of sebaceous hyperplasia.

Typical facial papules appear in middle age, are larger than lesions on the areola or mouth, and display a central dell that corresponds to a central follicular infundibular ostium.

Next

Pathophysiology

Sebaceous glands are found throughout the skin except on the palms and soles. They exist as a component of the pilosebaceous unit or, less frequently, open directly to the epithelial surface in areas of modified skin, including the lips and buccal mucosa (as Fordyce spots), glans penis or clitoris (as Tyson glands), areolae (as Montgomery glands), and eyelids (as meibomian glands). The largest sebaceous glands and the greatest number of sebaceous glands are found on the face, chest, back, and the upper outer arms.

These holocrine glands are composed of acini attached to a common excretory duct. The life cycle of the sebocytes, the cells that form the sebaceous gland, begins at the periphery of the gland in the highly mitotic basal cell layer; as the sebocytes differentiate and mature, they accumulate increasing amounts of lipid and migrate toward the central excretory duct. The mature sebocytes complete their life cycle as they reach the central duct and release their lipid content as sebum by disintegrating. The turnover time of the sebocytes as they migrate from the basal layer of the gland to the central duct is approximately 1 month.

Sebaceous glands are highly androgen sensitive, and, although the number of sebaceous glands remains approximately the same throughout life, their activity and size vary according to age and circulating hormone levels. The sebaceous glands, as well as the sweat glands, account for the vast majority of androgen metabolism in the skin.

The enzymes found in the sebocytes that are involved in androgen metabolism include 5-alpha-reductase type I, 3-beta-hydroxysteroid dehydrogenase, and 17-beta-hydroxysteroid dehydrogenase type II. These enzymes metabolize the relatively weak circulating androgens, such as dehydroepiandrosterone-sulfate, into the more potent androgens, such as dihydrotestosterone; these potent androgens, in turn, bind to receptors within the sebocytes, resulting in an increase in the size and metabolic rate of the sebaceous gland. Studies have shown that the activity of 5-alpha-reductase is higher in the scalp and facial skin than in other areas, so that testosterone and dihydrotestosterone stimulate more sebaceous gland proliferation in these areas. Estrogens have been found to decrease sebaceous gland secretion.

In the perinatal period, the sebaceous glands are initially large and are likely responsible for the production of vernix caseosa often seen in newborns; the activity and size of the sebaceous glands regress shortly after birth, due to withdrawal of maternal hormones, and remain small throughout infancy and childhood. At puberty, sebaceous glands enlarge and become increasingly active due to increased production of androgens, and they reach their maximum by the third decade of life. As androgen levels decrease with advancing age, the sebocyte turnover begins to slow down.

This decrease in cellular turnover results in crowding of primitive sebocytes within the sebaceous gland, causing a benign enlargement of the sebaceous gland, or sebaceous hyperplasia. This is particularly apparent in the areas where sebaceous glands are concentrated, such as the face. Although the hyperplastic glands are often inflated up to 10 times their normal size, they secrete very little sebum. In contrast to normal sebocytes that are engorged with lipid, the hyperplastic sebaceous glands contain small undifferentiated sebocytes with large nuclei and scant cytoplasmic lipid.

Sebaceous hyperplasia has also been linked to long-term immunosuppression in posttransplantation patients taking cyclosporin A. Although the mechanism for this reaction is poorly understood, this adverse effect is thought to be specific for the highly lipophilic cyclosporin A; other immunosuppressants have not been associated with an increased prevalence of sebaceous hyperplasia.

Although more commonly found in the older population, premature or familial cases have been reported in which younger individuals are affected with multiple lesions, suggesting a genetic predisposition. In these cases of premature familial sebaceous hyperplasia, extensive sebaceous hyperplasia appears at puberty and tends to progress with age.[15, 16, 17]

Previous
Next

Epidemiology

Frequency

Sebaceous hyperplasia is a common skin finding in aging adults, reported to occur in approximately 1% of the healthy US population. However, the prevalence of sebaceous hyperplasia has been reported to be as high as 10-16% in patients receiving long-term immunosuppression with cyclosporin A.[18, 19, 20]

Sex

The difference in prevalence between men and women is unknown.

Age

Sebaceous hyperplasia is common in newborns.[21] Of 1000 consecutive neonates examined in an Iranian prospective cohort study, 43.7% had sebaceous hyperplasia.[22]

Typical facial papules begin to appear in middle age (usually fifth or sixth decade) and continue to appear into later life.

Previous
Next

Prognosis

Mortality/Morbidity

Sebaceous hyperplasia has no direct association with malignant degeneration and is not a cause of morbidity, except perhaps related to cosmesis. Sebaceous hyperplasia has been reported in association with internal malignancy in the setting of Muir-Torre syndrome. Muir-Torre syndrome is a rare autosomal dominant disorder in which visceral malignancies, sebaceous neoplasms (eg, sebaceous adenoma, sebaceous carcinoma), and keratoacanthoma coincide. Colon cancer is the leading internal malignancy associated with Muir-Torre syndrome, followed by hematologic malignancies.[23] Sebaceous hyperplasia alone does not signify a predisposition to cancer or represent a sign of Muir-Torre syndrome.

One study found that 29.9% of patients with a renal transplant had sebaceous hyperplasia; 45.7% of these patients had a history of nonmelanoma skin cancer, compared with 7.3% of patients without sebaceous hyperplasia.[13] This strong association of nonmelanoma skin cancer with sebaceous hyperplasia remained significant after correction of factors such as age, sex, skin type, and duration since the transplantation.

Previous
 
 
Contributor Information and Disclosures
Author

Daniel J Hogan, MD Clinical Professor of Internal Medicine (Dermatology), Nova Southeastern University College of Osteopathic Medicine; Investigator, Hill Top Research, Florida Research Center

Daniel J Hogan, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Contact Dermatitis Society, Canadian Dermatology Association

Disclosure: Nothing to disclose.

Coauthor(s)

Stephen H Mason, MD 

Stephen H Mason, MD is a member of the following medical societies: American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery, Women's Dermatologic Society, Skin Cancer Foundation

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Steven R Feldman, MD, PhD Professor, Departments of Dermatology, Pathology and Public Health Sciences, and Molecular Medicine and Translational Science, Wake Forest Baptist Health; Director, Center for Dermatology Research, Director of Industry Relations, Department of Dermatology, Wake Forest University School of Medicine

Steven R Feldman, MD, PhD is a member of the following medical societies: American Academy of Dermatology, American Society of Dermatopathology, North Carolina Medical Society, Society for Investigative Dermatology

Disclosure: Received honoraria from Amgen for consulting; Received honoraria from Abbvie for consulting; Received honoraria from Galderma for speaking and teaching; Received consulting fee from Lilly for consulting; Received ownership interest from www.DrScore.com for management position; Received ownership interest from Causa Reseasrch for management position; Received grant/research funds from Janssen for consulting; Received honoraria from Pfizer for speaking and teaching; Received consulting fee from No.

Chief Editor

William D James, MD Paul R Gross Professor of Dermatology, Vice-Chairman, Residency Program Director, Department of Dermatology, University of Pennsylvania School of Medicine

William D James, MD is a member of the following medical societies: American Academy of Dermatology, Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Additional Contributors

Arash Taheri, MD Research Fellow, Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine

Disclosure: Nothing to disclose.

Acknowledgements

R Walker Jones, MD Harris M Blackman, MD, LLC

R Walker Jones, MD is a member of the following medical societies: American Chemical Society, American Medical Association, American Medical Student Association/Foundation, and Louisiana State Medical Society

Disclosure: Nothing to disclose.

References
  1. Hogan DJ. Sebaceous hyperplasia of the chest. Int J Dermatol. 1991 Apr. 30(4):306. [Medline].

  2. Krisp A, Krause W. Areolar sebaceous hyperplasia. Acta Derm Venereol. 2003. 83(1):61-2. [Medline].

  3. Daley TD. Intraoral sebaceous hyperplasia. Diagnostic criteria. Oral Surg Oral Med Oral Pathol. 1993 Mar. 75(3):343-7. [Medline].

  4. Ma HJ, Zhao G, Wang YX. Sebaceous hyperplasia of the scrotum in an adolescent boy. Pediatr Dermatol. 2007 May-Jun. 24(3):340-2. [Medline].

  5. Ena P, Origa D, Massarelli G. Sebaceous gland hyperplasia of the foreskin. Clin Exp Dermatol. 2009 Apr. 34(3):372-4. [Medline].

  6. Ju HY, Kim HS, Kim HO, Park YM. Sebaceous hyperplasia of the penile shaft. J Eur Acad Dermatol Venereol. 2009 Apr. 23(4):443-4. [Medline].

  7. Bakaris S, Kiran H, Kiran G. Sebaceous gland hyperplasia of the vulva. Aust N Z J Obstet Gynaecol. 2004 Feb. 44(1):75-6. [Medline].

  8. Malliah R, Gilhooly P, Lambert WC, Heller DS. Sebaceous hyperplasia of the vulva: case report and review of the literature. J Low Genit Tract Dis. 2006 Jan. 10(1):55-7. [Medline].

  9. Rocamora A, Santonja C, Vives R, Varona C. Sebaceous gland hyperplasia of the vulva: a case report. Obstet Gynecol. 1986 Sep. 68(3 Suppl):63S-65S. [Medline].

  10. Kato N, Yasuoka A. "Giant" senile sebaceous hyperplasia. J Dermatol. 1992 Apr. 19(4):238-41. [Medline].

  11. Finan MC, Apgar JT. Juxta-clavicular beaded lines: a subepidermal proliferation of sebaceous gland elements. J Cutan Pathol. 1991 Dec. 18(6):464-8. [Medline].

  12. Marini M, Saponaro A, Remorino L, Lynch P, Magarinos G. Eruptive lesions in a patient with bone marrow transplantation. Int J Dermatol. 2001 Feb. 40(2):133-5. [Medline].

  13. Salim A, Reece SM, Smith AG, et al. Sebaceous hyperplasia and skin cancer in patients undergoing renal transplant. J Am Acad Dermatol. 2006 Nov. 55(5):878-81. [Medline].

  14. de Berker DA, Taylor AE, Quinn AG, Simpson NB. Sebaceous hyperplasia in organ transplant recipients: shared aspects of hyperplastic and dysplastic processes?. J Am Acad Dermatol. 1996 Nov. 35(5 Pt 1):696-9. [Medline].

  15. Dupre A, Bonafe JL, Lamon P. Functional familial sebaceous hyperplasia of the face and premature sebaceous gland hyperplasia: a new and unique entity. J Am Acad Dermatol. 1983 Nov. 9(5):768-9. [Medline].

  16. Grimalt R, Ferrando J, Mascaro JM. Premature familial sebaceous hyperplasia: successful response to oral isotretinoin in three patients. J Am Acad Dermatol. 1997 Dec. 37(6):996-8. [Medline].

  17. Wang Q, Liu JM, Zhang YZ. Premature sebaceous hyperplasia in an adolescent boy. Pediatr Dermatol. 2011 Mar-Apr. 28(2):198-200. [Medline].

  18. Boschnakow A, May T, Assaf C, Tebbe B, Zouboulis ChC. Ciclosporin A-induced sebaceous gland hyperplasia. Br J Dermatol. 2003 Jul. 149(1):198-200. [Medline].

  19. Engel F, Ellero B, Woehl-Jaegle ML, Cribier B. [Diffuse sebaceous hyperplasia of the face induced by cyclosporine]. Ann Dermatol Venereol. 2005 Apr. 132(4):342-5. [Medline].

  20. McDonald SK, Goh MS, Chong AH. Successful treatment of cyclosporine-induced sebaceous hyperplasia with oral isotretinoin in two renal transplant recipients. Australas J Dermatol. 2011 Aug. 52(3):227-30. [Medline].

  21. Kanada KN, Merin MR, Munden A, Friedlander SF. A prospective study of cutaneous findings in newborns in the United States: correlation with race, ethnicity, and gestational status using updated classification and nomenclature. J Pediatr. 2012 Aug. 161(2):240-5. [Medline].

  22. Moosavi Z, Hosseini T. One-year survey of cutaneous lesions in 1000 consecutive Iranian newborns. Pediatr Dermatol. 2006 Jan-Feb. 23(1):61-3. [Medline].

  23. Johnson PJ, Heckler F. Muir-Torre syndrome. Ann Plast Surg. 1998 Jun. 40(6):676-7. [Medline].

  24. Argenziano G, Zalaudek I, Corona R, et al. Vascular structures in skin tumors: a dermoscopy study. Arch Dermatol. 2004 Dec. 140(12):1485-9. [Medline].

  25. Bryden AM, Dawe RS, Fleming C. Dermatoscopic features of benign sebaceous proliferation. Clin Exp Dermatol. 2004 Nov. 29(6):676-7. [Medline].

  26. Zaballos P, Ara M, Puig S, Malvehy J. Dermoscopy of sebaceous hyperplasia. Arch Dermatol. 2005 Jun. 141(6):808. [Medline].

  27. Oztas P, Polat M, Oztas M, Alli N, Ustun H. Bonbon toffee sign: a new dermatoscopic feature for sebaceous hyperplasia. J Eur Acad Dermatol Venereol. 2008 Nov. 22(10):1200-2. [Medline].

  28. Alexiades-Armenakas M. Laser-mediated photodynamic therapy. Clin Dermatol. 2006 Jan-Feb. 24(1):16-25. [Medline].

  29. Horio T, Horio O, Miyauchi-Hashimoto H, Ohnuki M, Isei T. Photodynamic therapy of sebaceous hyperplasia with topical 5-aminolaevulinic acid and slide projector. Br J Dermatol. 2003 Jun. 148(6):1274-6. [Medline].

  30. Bader RS, Scarborough DA. Surgical pearl: intralesional electrodesiccation of sebaceous hyperplasia. J Am Acad Dermatol. 2000 Jan. 42(1 Pt 1):127-8. [Medline].

  31. Rosian R, Goslen JB, Brodell RT. The treatment of benign sebaceous hyperplasia with the topical application of bichloracetic acid. J Dermatol Surg Oncol. 1991 Nov. 17(11):876-9. [Medline].

  32. Aghassi D, Gonzalez E, Anderson RR, Rajadhyaksha M, Gonzalez S. Elucidating the pulsed-dye laser treatment of sebaceous hyperplasia in vivo with real-time confocal scanning laser microscopy. J Am Acad Dermatol. 2000 Jul. 43(1 Pt 1):49-53. [Medline].

  33. Walther T, Hohenleutner U, Landthaler M. [Sebaceous gland hyperplasia as a side effect of cyclosporin A. Treatment with the CO2 laser]. Dtsch Med Wochenschr. 1998 Jun 19. 123(25-26):798-800. [Medline].

  34. Yu C, Shahsavari M, Stevens G, Liskanich R, Horowitz D. Isotretinoin as monotherapy for sebaceous hyperplasia. J Drugs Dermatol. 2010 Jun. 9(6):699-701. [Medline].

 
Previous
Next
 
Normal sebaceous gland histology. Courtesy of Cooper Heard, MD.
Histology of sebaceous hyperplasia; enlarged sebaceous gland with multiple lobules grouped around a central dilated sebaceous duct. Courtesy of Cooper Heard, MD.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.